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The ARF and p53 tumor suppressors are thought to
act in a linear pathway to prevent cellular transforma-
tion in response to various oncogenic signals. Here,
we show that loss of p53 leads to an increase in
ARF protein levels, which function to limit the prolif-
eration and tumorigenicity of p53-deficient cells by
inhibiting an IFN-b-STAT1-ISG15 signaling axis. Hu-
man triple-negative breast cancer (TNBC) tumor
samples with coinactivation of p53 and ARF exhibit
high expression of both STAT1 and ISG15, and
TNBC cell lines are sensitive to STAT1 depletion.
We propose that loss of p53 function and subse-
quent ARF induction creates a selective pressure
to inactivate ARF and propose that tumors harbor-
ing coinactivation of ARF and p53 would benefit
from therapies targeted against STAT1 and ISG15
activation.INTRODUCTION
The CDKN2A and TP53 tumor-suppressor genes are two of the
most frequently inactivated genomic loci in human cancers
(Sherr et al., 2005). CDKN2A encodes two unrelated proteins,
p14ARF (p19ARF in mice) and p16INK4A, both of which function
as tumor suppressors (Quelle et al., 1995). This unprecedented
genomic organization leads to the sharing of exons 2 and 3 by
ARF and p16, but due to distinct promoters and first exons,
ARF is translated in an alternative reading frame, hence its
name. p16 is a well-characterized cyclin-dependent kinase in-
hibitor, and functions to keep the retinoblastoma protein (Rb)
in a hypophosphorylated state, effectively blocking entry into S
phase of the cell cycle (Roussel, 1999). ARF, in response to hy-
perproliferative and hypergrowth cues, induces p53 stabilization
by binding to and sequestering the p53 E3 ubiquitin ligaseMDM2
in the nucleolus (Saporita et al., 2007; Zindy et al., 1997). Relief of
the inhibitory effects of MDM2 allows p53 to activate transcrip-
tional programs leading to cell-cycle arrest or apoptosis (Riley
et al., 2008). Thus, ARF and p53 are thought to function in a linear514 Cell Reports 7, 514–526, April 24, 2014 ª2014 The Authorsgenetic pathway that functions to protect cells from inappro-
priate oncogenic signaling (Sherr, 2001).
Since ARF’s initial discovery, it has been observed that cells
lacking p53 function contain elevated levels of ARF (Quelle
et al., 1995; Stott et al., 1998; Zindy et al., 1998). A mechanistic
explanation for this phenomenon surfaced when it was recently
shown that p53 is a potent transcriptional repressor of the
CDKN2A promoter. Recruitment of histone deacetylases and
Polycomb group proteins by p53 renders the locus inaccessible
to transcription factors (Zeng et al., 2011). Thus, in the context of
p53 loss of function, ARF transcription is derepressed and
protein levels become elevated. It is heavily debated whether
these induced protein levels are functional.
Mounting evidence suggests ARF possesses important p53-
independent tumor-suppressor functions, supported by the
findings that TP53 and CDKN2A are frequently coinactivated in
human cancers (Cancer Genome Atlas Research Network,
2012; O’Dell et al., 2012; Rozenblum et al., 1997; Sanchez-Ces-
pedes et al., 1999; Saporita et al., 2007; Sherr, 2006). Admittedly,
it remains unclear which CDKN2A gene product, ARF or p16, is
selected against in tumors. However, several groups have
shown that p53-null cells are sensitive to exogenous overexpres-
sion of ARF, demonstrating that ARF can function independently
of p53 to inhibit proliferation and suggesting a selective pressure
might exist to selectively silence ARF in the absence of p53
(Sherr, 2006; Sherr et al., 2005; Weber et al., 2000). Here, we
show that acute p53 loss results in an induction of ARF protein
expression and that this endogenous ARF accumulation func-
tions to limit the proliferation and tumorigenicity of p53-deficient
cells. Furthermore, we demonstrate that this elevated ARF
expression inhibits a protumorigenic signaling cascade medi-
ated by interferon b (IFN-b) secretion and activation of the
STAT1 transcription factor. We propose that in the absence of
both p53 and ARF, IFN signaling is undeterred and cellular trans-
formation is enhanced, a finding that we substantiate in primary
human breast cancers.
RESULTS
Acute p53 Loss Induces Functional ARF
It has long been assumed that the high levels of ARF found
in p53-deficient cells are not tumor suppressive. To directly
Figure 1. Acute Loss of p53 Induces Functional ARF
(A) Western blot analysis of cell lysates from p53flox/flox MEFs infected with Ad-LacZ (L) or Ad-Cre (C) harvested at the indicated time points. Fold change of ARF
levels are relative to Ad-LacZ control.
(B) qRT-PCR analysis of p53 and ARF mRNA levels from p53flox/flox MEFs infected with Ad-LacZ or Ad-Cre. mRNA levels were normalized to b-actin, and fold
changes are relative to Ad-LacZ controls. Error bars represent SD for n = 3 from three independent experiments.
(C) Proliferation assay performed with cells described in (A) and (B).
(D) Ad-LacZ- or Ad-Cre-infected p53flox/flox MEFs pulsed with BrdU for 4 hr. BrdU- and DAPI-positive nuclei were visualized using immunofluorescence, and data
represent percent BrdU-positive nuclei from three independent experiments.
(E) Representative image of foci assay with Ad-LacZ or Ad-Cre infected p53flox/flox MEFs.
(F) Western blot analysis of dp53 MEFs infected with shSCR or shARF.
(G) Equal numbers of dp53 MEFs infected with shSCR or shARF were plated and manually counted on the indicated days.
(H) Representative image of foci assay performed with dp53 MEFs expressing shSCR or shARF.
See also Figure S2.address this assumption, we utilized a conditional mouse model
of p53 inactivation where exons 2–10 are flanked by loxP sites
(Jonkers et al., 2001). Adenoviral (Ad) delivery of Cre-recombi-
nase into p53flox/flox mouse embryonic fibroblasts (MEFs) re-
sulted in an accumulation of ARF mRNA and protein by 4 days
postinfection, and levels continued to rise over time and passage
(Figures 1A and 1B). These data are in agreement with previousfindings that p53 directly binds to and is capable of repressing
the ARF promoter (Zeng et al., 2011). Importantly, a transcrip-
tional target of p53, MDM2, was reduced following excision of
p53 (Figure 1A).
These p53D/D MEFs, hereafter referred to as dp53 cells
(deleted for p53), proliferated faster than LacZ-infected controls,
exhibited more rapid S phase entry, and formed numerous fociCell Reports 7, 514–526, April 24, 2014 ª2014 The Authors 515
when plated at low density (Figures 1C–1E). Infection of dp53
MEFs with a short hairpin RNA (shRNA) specifically targeting
ARF resulted in further enhancement of proliferation and foci
formation (Figures 1F–1H), indicating that the proliferation of
p53-deficient cells is constrained by endogenously induced
ARF protein. Importantly, shRNA-mediated depletion of ARF
did not reduce p16 levels, indicating the observed enhancement
of proliferation was specifically due to ARF loss (Figure S2A).
Endogenous ARF Limits the Tumorigenicity of
p53-Deficient Cells
To test the tumor-suppressive functions of ARF in the context of
p53 loss, we overexpressed mutant H-RasV12 in dp53 MEFs and
then depleted ARF (Figure 2A). As seen in Figure 2, RasV12-trans-
formed dp53 MEFs (dp53R MEFs) were capable of forming col-
onies in soft agar (Figure 2B, top left panel). However, depletion
of ARF in the dp53R MEFs resulted in a tremendous increase in
the size of soft agar colonies, indicating an increase in tumori-
genic potential (Figures 2B and 2C). The dp53R-shARF MEFs
also exhibited higher proliferative rates, bromodeoxyuridine
(BrdU) incorporation rates, and increased foci formation com-
pared to dp53R-shSCR cells, supporting our observed tumori-
genic phenotype (Figures 2D–2F). To extend our findings in vivo,
we injected the dp53R-shARF cells into the flanks of nude mice.
We observed a striking enhancement in the growth kinetics of
dp53R-shARF tumors relative to tumors formed with dp53R-
shSCR cells (Figures 2G and 2H). Taken together, these data
demonstrate the endogenous ARF levels that accumulate
following p53 loss function to limit tumorigenicity.
ARF Inhibits an Interferon-Sensitive Gene Signature
Induced upon p53 Loss
Having demonstrated that the induced levels of ARF in p53-defi-
cient cells serve a tumor-suppressive function (Figure 2), we
sought to understand which oncogenic processes ARF might
be inhibiting to limit tumorigenicity. The previously ascribed
p53-independent tumor-suppressive roles of ARF include regu-
lating general or mRNA-specific translation (Apicelli et al., 2008;
Kawagishi et al., 2010; Kuchenreuther and Weber, 2014; Sugi-
moto et al., 2003), inhibition of transcription factors such as
c-Myc (Qi et al., 2004), and modulation of protein sumoylation
(Kuo et al., 2008). We analyzed these processes in our system
and observed no significant differences between dp53R-shSCR
and dp53R-shARF MEFs (data not shown).
Therefore,we tookanunbiasedapproach to identify changes in
global mRNA expression between dp53R-shSCR and dp53R-
shARFMEFs.Comparativemicroarrayanalysis yieldednumerous
upregulated immune response genes in the dp53R-shARF cells,
including Irf7, Oasl2, Ifit3, Usp18, Mx2, and Isg15 (Figures 3A
and 3B). Pathway analysis indicated that the gene signature
was most strongly associated with the innate immune response
or type I IFN response (Figure 3B). The interferon-sensitive gene
(ISG) expression changes were validated by quantitative RT-
PCR (qRT-PCR) (Figure 3C).
As an important control, we analyzed ISG expression in our
cell lines following infection with the various viral constructs
used in our experiments and compared to mRNA levels in
‘‘mock’’-infected cells (no virus). Retroviral infection with empty516 Cell Reports 7, 514–526, April 24, 2014 ª2014 The Authorsvector or RasV12 did not induce ISGs, and lentiviral infection of
Arf-null or wild-type MEFs with shSCR or shARF had no effect
on ISGmRNA levels (Figures S1A–S1C). Furthermore, a compar-
ison of three different low-passage (<passage 6) wild-type and
Arf-null MEF lines showed no increase in ISG expression (Fig-
ure S1D). The only genetic setting where ARF depletion induced
ISGs was in the context of p53 deficiency (Figure S1E). Addi-
tional experiments were performed to assess the role of
p16INK4a in ISG induction. As shown in Figure S2, an shRNA tar-
geting both ARF and p16 was unable to induce an additive effect
on ISG expression (Figures S2B and S2C). Moreover, specific
depletion of p16 in dp53R MEFs did not induce ISG expression
(Figures S2D and S2E). Thus, ARF’s inhibition of ISG expression
is entirely dependent on a p53-deficient genetic setting, and p16
knockdown does not produce the same effects.
Given ARF’s ability to inhibit ISG expression exclusively in the
context of p53 deficiency, we hypothesized that loss of p53
might be the driving force behind upregulation of the ISGs and
that the induction of ARF would then serve as a biological
‘‘brake’’ to suppress the response. To test this hypothesis, we
analyzed ISG mRNA expression following infection of p53flox/flox
MEFs with Ad-Cre or -LacZ control. As shown in Figure 3D,
expression of ISG15 and OASL2 are induced at 4 and 6 days
after p53 loss. Consistent with our hypothesis, 8 days after p53
loss, when ARF protein levels are maximally induced, we no
longer observed a significant induction of the ISGs (Figures 3D
and 3E). The suppression of ISG15 and OASL2 expression
8 days after p53 loss was completely relieved when ARF-specific
shRNA was introduced. Therefore, the negative feedback p53
imposes on ARF exists to allow ARF to respond to acute p53
loss by inhibiting an induction of ISGs.
Having demonstrated ARF and p53 cooperate to suppress
expression of ISGs in vitro, we sought to establish the existence
of this signaling pathway in vivo. We generated cohorts of Blg-
Cre;p53flox/flox;Arf+/+ and Blg-Cre;p53flox/flox;Arf flox/flox mice to
analyze the effects of losing p53 alone versus losing both Arf
and p53. Activation of Cre-recombinase by the beta-lactoglob-
ulin (Blg) promoter induces recombination of floxed alleles spe-
cifically in the mammary gland of lactating female mice (Selbert
et al., 1998). Tumors isolated from Blg-Cre;p53flox/flox;Arf flox/flox
mice expressed 3.5-fold more ISG15mRNA than those obtained
from Blg-Cre;p53flox/flox;Arf +/+ mice (Figures S3A and S3B). This
result is in support of the hypothesis that p53 and ARF cooperate
to suppress ISG expression in vivo and clearly demonstrates the
observed ISG induction is not simply an artifact of tissue culture.
IFN-b Is Necessary and Sufficient for Increased
Tumorigenicity in dp53R-shARF MEFs
Our microarray data and pathway analysis indicated an activa-
tion of the type I IFN response, or more specifically, response
to IFN-b. We analyzed IFN-b mRNA expression using qRT-
PCR in our dp53R-shARF MEFs and consistently observed a
2- to 3-fold induction (Figure 4A). Additionally, this 3-fold induc-
tion of IFN-bmRNA resulted in a nearly 11-fold increase in IFN-b
secretion in the media containing dp53R-shARF cells as
measured by ELISA (Figure 4B). To determine the requirement
of secreted IFN-b for cell proliferation, we knocked down IFN-b
in dp53R-shARF cells. This resulted in a significant decrease in
Figure 2. Endogenous ARF Limits the Tumorigenicity of p53-Deficient Cells
(A) Western blot analysis of dp53 MEFs expressing RasV12 (dp53R) and infected with shSCR or shARF.
(B and C) Representative images of dp53R-shSCR or dp53R-shARFMEFs growing in soft agar. Macroscopic colonies were quantified in (C). Error bars represent
SD of n = 3.
(D) Proliferation assay of dp53 MEFs expressing empty vector or RasV12 and infected with shARF or shSCR control.
(E) Percent BrdU-positive nuclei of cells described in (D) following 4 hr pulse with BrdU. Error bars represent SD from three independent measurements of
100 nuclei.
(F) Representative image of foci assay performed with dp53R MEFs expressing shSCR or shARF.
(G) Images of tumor-bearing mice and excised tumors from allograft experiments using dp53R-shARF or shSCR MEFs.
(H) Tumor size was measured using calipers on the indicated days postinjection. Tumor size (volume) was calculated as described in Experimental Procedures.
Error bars represent SD of n = 5.both IFN-b expression and phosphorylated STAT1 (Figures 4C
and 4D). Long-term proliferation was significantly impaired in
cells with reduced IFN-b (Figure 4E), indicating a requirement
for IFN-b production in dp53R-shARF cells.Next, we sought to determine if enhanced production of IFN-b
was sufficient to promote the aberrant proliferation of dp53R
cells in the presence of high ARF levels. Using concentrations
of recombinant IFN-b that matched the concentration rangeCell Reports 7, 514–526, April 24, 2014 ª2014 The Authors 517
Figure 3. ARF Inhibits an Interferon-Sensitive Gene Signature Induced upon p53 Loss
(A) Western blot verifying overexpression of RasV12 and knockdown of ARF in dp53 MEFs. RNA from three independent experiments was submitted for
microarray analysis.
(B) Heatmap showing significantly altered genes (>2-fold change) and pathway analysis of significantly altered genes in the data set.
(C) Validation of ISGs with qRT-PCR. Levels were normalized to histone 3.3 mRNA and are relative to shSCR controls. Error bars represent SD from three
independent experiments.
(D) qRT-PCR analysis of p53flox/flox MEFs infected with Ad-LacZ or Ad-Cre from the indicated time points postinfection. Cells were all infected with shSCR() or
shARF(+) 1 day after Cre-infection as indicated. mRNA levels are relative to Ad-LacZ-shSCR controls and represent averages of three independent experiments.
(E) Western blot analysis of cells described in (D).
See also Figures S1–S3.detected in the media of dp53R-shARF cells, we observed a sig-
nificant increase in long-term proliferation of dp53R cells that
was comparable to that seen in dp53R-shARF cells (Figure 4G).
Markedly, recombinant IFN-b stimulated ISG15 expression to
the same level seen in dp53R-shARF cells (Figure 4F). Therefore
IFN-b production is sufficient to phenocopy the signaling
pathway activation and proliferative gains seen with ARF knock-
down in dp53R cells.
ARF Represses a Protumorigenic STAT1-ISG15
Signaling Cascade
Canonical IFN-b signaling occurs upon ligand binding to the
membrane receptors IFNAR1/2. Upon ligand binding, a confor-
mational change allows autophosphorylation of receptor-bound
JAK1 and TYK2. The activation of these kinases leads to phos-
phorylation of STAT1 and STAT2 proteins, which enables them518 Cell Reports 7, 514–526, April 24, 2014 ª2014 The Authorsto enter the nucleus. Once inside the nucleus, the STAT1/
STAT2 heterodimer associates with IRF9 to form a complex
known as interferon-stimulated gene factor 3 (ISGF3), which is
fully capable of initiating transcription of genes containing inter-
feron-stimulated response elements (ISREs) (Platanias, 2005).
Many of the genes in our ISG signature contain ISREs in their
promoters (Sadler and Williams, 2008), and it is well established
that activation of the STAT1 transcription factor is required for
upregulation of ISRE-containing genes (Ramana et al., 2000).
Therefore, we analyzed STAT1 status in dp53R-shARF cells
and observed increases in the phosphorylation of both tyrosine
701 and serine 727 activation sites as well as an accumulation
of total STAT1 levels (Figure 5A). Neither STAT3 activation nor
increased expression of its upstream cytokine, interleukin-6,
was observed in the same genetic context (Figure S4). The in-
crease in total STAT1 was due to an increase in mRNA levels,
Figure 4. IFN-b Signaling Is Necessary and Sufficient for Enhanced Tumorigenicity in dp53R-shARF MEFs
(A) qRT-PCR analysis of IFN-b mRNA levels in dp53R-shARF MEFs. Levels are normalized to histone 3.3 mRNA and relative to shSCR controls.
(B) Extracellular IFN-b concentration measured by ELISA in dp53R-shARF MEFs. Values are fold changes relative to shSCR control. Error bars represent SD of
three independent experiments.
(C) qRT-PCR analysis of dp53R-shSCR or -shARF MEFs infected with two specific shRNAs targeting IFN-b. Relative mRNA expression was obtained by
normalizing to histone 3.3 mRNA. Error bars represent SD of three independent measurements.
(D) Western blot analysis of cells described in (C) for the indicated proteins.
(E) Representative image of foci assay performed with dp53R-shARF or shSCR MEFs infected with two IFN-b-specific shRNAs. Quantification of three inde-
pendent measurements is shown (right).
(F) qRT-PCR analysis of dp53R-shSCR or –shARF cells treated with the indicated concentration of IFN-b. Error bars represent SD of values from three inde-
pendent measurements.
(G) Representative image of foci assay performed with dp53R-shARF or shSCR MEFs treated with the indicated concentration of recombinant IFN-b. Quanti-
fication of three independent measurements is shown (right). *p < 0.01consistent with the observation that the STAT1 promoter con-
tains an ISRE (Figure 5B) (Zimmerman et al., 2012).
To test whether STAT1-mediated signaling was required for
the increased tumorigenicity in the dp53R-shARF MEFs, weused shRNAs to deplete STAT1. Reducing total STAT1 protein
levels led to a concomitant decrease in phosphorylation in
dp53R-shARF MEFs (Figure 5C). As shown in Figure 5D,
mRNA expression of select ISGs was also reduced followingCell Reports 7, 514–526, April 24, 2014 ª2014 The Authors 519
Figure 5. STAT1 Activation Is Required for Increased Tumorigenicity in dp53R-shARF MEFs
(A) Western blot analysis of dp53R-shARF or shSCR MEFs showing STAT1 activation.
(B) qRT-PCR analysis of total STAT1 mRNA levels in dp53R-shARF MEFs. mRNA levels are relative to shSCR controls and normalized to histone 3.3.
(C) Western blot analysis of dp53R-shSCR or shARF MEFs infected with two different STAT1 shRNAs.
(D) qRT-PCR analysis of dp53R-shSCR or shARF MEFs infected with control or two different STAT1 shRNAs.
(E) Proliferation assay of dp53R MEFs expressing the indicated shRNAs.
(F) Representative images of foci assays with dp53R MEFs expressing the indicated shRNAs.
(G) Soft agar quantification of STAT1-depleted dp53R-shARF MEFs.
All error bars represent SD for n = 3. *p < 0.0004, **p < 0.009. See also Figure S4.STAT1 knockdown. Short and long-term proliferation of dp53R-
shARF MEFs was inhibited and colony growth in soft agar was
reduced (Figures 5E–5G). Taken together, these data indicate520 Cell Reports 7, 514–526, April 24, 2014 ª2014 The Authorsthat ARF protects p53-deficient cells from inappropriate STAT1
activation and, if left unchecked, signaling through STAT1 can
lead to increased tumorigenicity.
Figure 6. ISG15 Is Required for Increased Tumorigenicity in dp53R-shARF MEFs
(A) Western blot analysis of ISG15 expression in dp53R-shARF MEFs. Free and conjugated forms are indicated.
(B) Western blot analysis of dp53R-shSCR or shARF MEFs expressing an shRNA specifically targeting ISG15.
(C) Quantification of macroscopic soft agar colony number with cells described in (B).
(D) Representative image of foci experiment from dp53R MEFs infected with the indicated shRNAs.
(E) Proliferation assay for dp53R MEFs infected with the indicated shRNAs.
All error bars represent SD of n = 3.Interestingly, one of the IFN-responsive genes, Isg15, encodes
a ubiquitin-like protein that is conjugated to lysine residues and
has recently been shown to be required for the tumorigenicity
of select breast cancer cell lines (Burks et al., 2014). Increased
ISG15 expression in dp53R-shARF MEFs is dependent upon
STAT1 (Figure 5D), so we hypothesized ISG15 might represent
one of the protumorigenic targets activated downstream of
STAT1. Western blot analysis confirmed upregulation of both
free and conjugated species of ISG15 in dp53R-shARF cells
(Figure 6A). Using an shRNA specific to ISG15, we observed a
significant reduction in soft agar growth, foci formation, and pro-
liferation in the dp53R-shARF MEFs upon ISG15 knockdown
(Figures 6B–6E), indicating that elevated ISG15 is required for
the tumorigenesis of dp53R-shARF cells.
Analysis of TNBC Patient Samples and Cell Lines
We have demonstrated that ARF protein induced by p53 loss
protects against the tumorigenic accumulation of an ISG signa-
ture in a mouse model system. To investigate whether thispattern of regulation was conserved in human cells, we focused
on triple-negative breast cancer (TNBC) because over 80% of
these patients harbor p53 mutations (Ellis and Perou, 2013).
We performed immunohistochemical analysis on an annotated
breast cancer tissue array and scored the triple-negative cores
(Table S1). Whereas elevated expression of ARF would be
expected in the presence of p53 mutation, we observed that
11 of the 13 samples with p53 mutation exhibited low or no
ARF staining, suggesting coinactivation of both ARF and p53.
Further, 6 of 11 tissues with both ARF and p53 loss of function
displayed intense staining of STAT1 and ISG15 (Figures 7A
and 7B).
Finally, we analyzed a panel of five TNBCcell lines. TheHCC70
cell line, which displayed high ARF protein expression, was
resistant to STAT1 depletion (Figures 7C, 7D, and S5A). The
other four cell lines, which did not express ARF, were all
extremely sensitive to STAT1 depletion, displaying signs of cyto-
toxicity (Figures 7C, 7D, and S5B). The short hairpins targeting
STAT1 did not reduce STAT3, a known promoter of breastCell Reports 7, 514–526, April 24, 2014 ª2014 The Authors 521
(legend on next page)
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cancer tumorigenesis (Marotta et al., 2011) (Figure S5C), con-
firming the selective requirement of STAT1 activation in con-
trolling the proliferation of these cells. Interestingly, the HCC70
cell line that was resistant to STAT1 depletion also expressed
the highest level of ISG15 among the TNBC cell lines assayed
(Figure S5A). We hypothesized that this cell line might have
upregulated ISG15 independently of STAT1-mediated transcrip-
tion. In agreement with this hypothesis, depletion of STAT1 in
HCC70 cells did not reduce ISG15 levels (Figure S6A). Given
our results in Figure 6, which indicated ISG15 is one of the
key protumorigenic effectors upon ARF depletion, we tested
whether depleting ISG15 in HCC70 cells would inhibit their pro-
liferation. Indeed, shRNA-mediated reduction of ISG15 signifi-
cantly reduced HCC70 cell proliferation (Figures S6B and
S6C). Taken together, these data demonstrate that inhibition of
type I IFN signaling components like STAT1 and ISG15 can
inhibit proliferation of TNBC cell lines and also that other deregu-
lated pathways in addition to ARF/p53 are likely capable of
inducing ISG expression.
DISCUSSION
Our work has provided an answer to a long-standing question
in cancer biology: What biological advantage does a normal
cell gain by having the p53 tumor suppressor repress tran-
scription of another tumor suppressor, ARF? We have shown
that loss of p53 leads to a potent induction of ARF protein
levels and that this large endogenous pool of ARF functions to
limit proliferation and tumorigenicity in the face of oncogenic
transformation.
To our surprise, depletion of ARF in p53-deficient cells led to
an induction of ISGs through secretion of IFN-b and activation
of the transcription factor STAT1. Our data further demonstrated
collaboration of p53 and ARF in suppressing STAT1 signaling
activation and subsequent ISG transcriptional activation both
in vitro and in vivo. This cooperation was specific to p53 and
ARF, because p16was not shown to be important in suppressing
ISG expression. Therefore, we propose that loss of p53 leads to
two important events: induction of ISGs and the induction of ARF
protein levels. Once ARF protein levels reach maximal expres-
sion, the transcription of ISGs is inhibited. In these cells, deletion
or mutation of the Arf locus would predict an upregulation of the
IFN gene signature and a subsequent tremendous growth
advantage. Therefore, our results suggest a selective pressure
does exist to coinactivate both ARF and p53, which indeed
occurs in several cancer types (Cancer Genome Atlas Research
Network, 2012; O’Dell et al., 2012; Rozenblum et al., 1997;
Sanchez-Cespedes et al., 1999).
Mechanistically, we do not yet understand how loss of p53
acts to induce expression of ISGs or how ARF functions to sup-Figure 7. Analysis of TNBC Patient Samples and Cell Lines
(A) Statistics from immunohistochemistry staining of human breast cancer tissue
(B) Representative images from immunohistochemistry displaying a section with
STAT1 (TNBC-2).
(C) Proliferation assays of the indicated TNBC cell lines infected with two differe
(D) Western blot analysis showing STAT1 depletion with shRNAs in various TNB
See also Figures S5 and S6 and Table S1.press the response. However, several recent publications are in
support of our findings and provide potential mechanistic expla-
nations. Cheon et al. showed that loss of p53 can induce
unphosphorylated STAT1, which was shown to function in an
unphosphorylated ISGF3 (U-ISGF3) complex to induce expres-
sion of select ISGs, providing resistance to DNA damaging
agents (Cheon et al., 2013). Many of these ISGs overlap with
the ones in our gene expression profile. Intriguingly, they also
demonstrated that low-level IFN-b, comparable to the levels
used in our studies, was capable of inducing activity of this
U-ISGF3 complex (Cheon et al., 2013). A recent report has
also suggested p53 is involved in suppressing the expression
of dsRNA from noncoding portions of the mouse genome (Leo-
nova et al., 2013). An increase in cellular dsRNA as a result of
endogenous insults can activate a type I IFN response (Chiappi-
nelli et al., 2012). Future studies will be necessary to explore
these possibilities. With regards to suppression of ISG expres-
sion by ARF, we have demonstrated that ARF and STAT1 can
interact in dp53 MEFs, and we are currently working to under-
stand the biological significance of this interaction (J.T.F., un-
published data).
While the activation of the type I IFN pathway is typically
observed in the context of viral defense, numerous groups
have found upregulation of this pathway in human cancers
(Buess et al., 2007; Duarte et al., 2012; Perou et al., 1999; Zim-
merman et al., 2012). The importance of IFN signaling in human
cancer is still a debated topic, but most commonly, activation of
a type I IFN signature is thought to be tumor suppressive (Chan
et al., 2012; Yu et al., 2009). In fact, type I IFN is an approved
treatment for many diverse cancer types (Dunn et al., 2006).
Our work provides evidence for the direct involvement of
IFN-b, STAT1, and a downstream ISG, ISG15, in promoting
tumorigenicity. Each of these components was required for the
enhanced tumorigenicity we observed in the dp53R-shARF
MEFs. Moreover, in cells lacking p53, recombinant IFN-b alone
was sufficient to stimulate proliferation.
Finally, we identified a subset of TNBC patients harboring
coinactivation of ARF and p53 alongside overexpression of
STAT1 and ISG15. Additionally, STAT1 depletion in a panel of
p53 mutant TNBC cell lines showed that only cells lacking ARF
expression were sensitive to the STAT1 shRNAs. Because exist-
ing mouse knockout models suggest that normal cells do not
require the activity of STAT1 and ISG15 for viability (Durbin
et al., 1996; Osiak et al., 2005), targeted therapy of this pathway
should be considered ideal for tumor reduction. Moreover, this
IFN signaling axis need not be limited to TNBC, because
numerous other cancers exhibit concomitant loss-of-function
p53 and ARF.
The crosstalk between p53 and ARF has proven to be a multi-
faceted affair. ARF is induced in response to oncogenic signalsarray.
high ARF staining (TNBC-1) and a section with low/no ARF and high ISG15/
nt STAT1 shRNAs.
C lines.
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to activate p53; ARF is also induced by loss of p53 to suppress
STAT1 signaling. Our findings support a model whereby induc-
tion of ARF following p53 loss acts to prevent aberrant IFN-b pro-
duction and signaling to crucial downstream effectors. Thus, the
functional links between p53 and ARF are far more imperative
than anticipated. The complex p53-ARF network that we have
identified provides tumor-suppressive redundancy where none
was thought to exist in cells. We believe our study, combined
with several recent reports, indicates a need to more carefully
examine the functional importance of IFN signaling in cancer
cells to ensure the use of IFN as a treatment option does not pro-
duce an undesirable outcome (Burks et al., 2014; Tsai et al.,
2011; Zimmerman et al., 2012). Moreover, our work suggests a
subset of human cancer patients, those containing p53 and
ARF mutations, might benefit from targeted inhibition of STAT1
or ISG15 activation.
EXPERIMENTAL PROCEDURES
Animal Studies
All animal studies were performed according to the guidelines established by
the Animal Studies Committee at Washington University in St. Louis. The
p53flox/flox (FVB.129-Trp53tm1Brn) mice were obtained from the National Cancer
Institute Mouse Repository and have been previously described (Jonkers
et al., 2001).
Cell Culture
Primary MEFs were isolated as previously described (Kamijo et al., 1997). All
cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% fetal bovine serum, 2 mM glutamine, 0.1 mM nones-
sential amino acids, 1 mM sodium pyruvate, and 2 mg/ml gentamicin. Recom-
binant IFN-b was obtained from PBL Interferon Source and used at the
indicated concentrations.
Viral Production and Infections
Adenoviruses expressing b-galactosidase (Ad-LacZ) or Cre recombinase (Ad-
Cre) were purchased from the Gene Transfer Vector Core, University of Iowa.
For adenoviral infections, 13 106 cells were plated in the presence of Ad-LacZ
or Ad-Cre (MOI = 50) and incubated for 8 hr. For mutant RasV12 overexpres-
sion, retrovirus was produced by transfecting 293T cells with either MSCV-
HRASV12-IRES-GFP plasmid or MSCV-IRES-GFP control and the helper
plasmid c-2. Virus-containing supernatants were harvested 48 hr posttrans-
fection. Collected retrovirus was used to infect 1 3 106 MEFs in the presence
of 10 mg/ml polybrene. For the production of lentiviral shRNAs, 293T cells were
transfected using Lipofectamine 2000 (Invitrogen) with pCMV-VSV-G, pCMV-
DR8.2, and pLKO.1-puro constructs. Viral supernatants were harvested 48 hr
posttransfection. Cells were infected with lentivirus for 8–12 hr in the presence
of 10 mg/ml protamine sulfate. Puromycin was added to cell culture media at a
concentration of 2 mg/ml for selection. The sequences of shRNAs are as
follows: STAT1-B4 50-GCCGAGAACATACCAGAGAAT-30 STAT1-B7 50- GCT
GTTACTTTCCCAGATATT-30 STAT1-A6 (human) 50- GAACAGAAATACACCT
ACGAA-30 STAT1-A9 (human) 50- CTGGAAGATTTACAAGATGAA-30 ISG15
50- AGCACAGTGATGCTAGTGGTA-30 IFN-b-1 50- GCAGAAGAGTTACACT
GCCTT-30 IFN-b-2 50- GCAGAGATCTTCAGGAACTTT-30. The ARF (mouse-
specific) hairpin was described previously (Apicelli et al., 2008).
Western Blotting
Cell pellets were lysed and sonicated in EBC lysis buffer (50 mM Tris-Cl
[pH 7.4], 120 mM NaCl, 0.5% NP-40, 1 mM EDTA) containing HALT Protease
and Phosphatase Inhibitor cocktail (Thermo Scientific) and 1 mM phenylme-
thanesulfonylfluoride. A total of 30 mg of protein were separated on SDS-poly-
acrylamide gels. Proteins were transferred to PVDF (Millipore) and probed with
antibodies. ARF (mouse), actin, p53 (human), g-tubulin, H-Ras, ISG15 (hu-
man), and STAT1 were all purchased from Santa Cruz Biotechnologies. p53524 Cell Reports 7, 514–526, April 24, 2014 ª2014 The Authors(mouse), phospho-STAT1Tyr701, phospho-STAT1Ser727, phospho-STAT3Tyr705,
and STAT3 were purchased from Cell Signaling. ARF (human) and GAPDH
were purchased from Bethyl Laboratories, and MDM2 was from Millipore.
Themouse ISG15 antibody was a gift from Dr. Deborah Lenschow. Secondary
horseradish peroxidase-conjugated antibodies (Jackson Immunoresearch)
were used, and ECL plus was used to visualize the bands (GE Healthcare).
Proliferation, BrdU, and Foci Assays
For proliferation assays, 5–10 3 104 cells were plated in six-well plates. Cells
were lifted and counted using a hemocytometer at the indicated number of
days postplating. For BrdU assays, 1 3 104 cells were plated on glass cover-
slips and incubated overnight. A total of 10 mM BrdU-containing media was
added to the cells for 4–6 hr. Cells were fixed with 10% formalin/methanol,
and BrdU staining was performed using a BrdU antibody (GE Healthcare)
according to the manufacturer’s instructions. For foci assays, 3 3 103 cells
were plated in 10 cm dishes and cells were incubated for 10 days. Cells
were fixed with 100% methanol and stained with Giemsa (Sigma Aldrich).
Soft Agar Assay
Cells were lifted and suspended in DMEM containing a final concentration of
0.4% noble agar. A total of 1.5 3 104 cells were layered in triplicate onto
0.6% noble-agar/media bottom layer in 60 mm plates. Plates were incubated
for 20 days, feeding with media/0.4% agar mix every 6 days. Macroscopic
colonies were visualized by staining with 0.005% crystal violet solution and
coloniesR0.5 mm were manually counted.
Tumorigenesis Assay
A total of 1.5 3 106 dp53R-shSCR or dp53R-shARF MEFs were resuspended
in PBS and injected into the flanks of female homozygous athymic nude mice
(Foxn1nu/Foxn1nu) obtained from Jackson Laboratory. Five mice per condition
were used. Tumor size was monitored over the course of 20 days using cali-
pers to measure in two dimensions. Tumor volume was calculated using the
formula: volume = [(height)2 3 length]/2, in which height equals the smallest
of the two measurements.
Microarray Analysis
RNA was isolated from dp53R-shSCR or dp53R-shARF MEFs using a
Nucleospin RNA II Kit (Clonetech). RNA samples from three independent ex-
periments were submitted to the Genome Technology Access Center at
Washington University School of Medicine for microarray analysis. Affymetrix
Gene 1.0ST arrays were used, and data were processed in Affymetrix Expres-
sion Console (Affymetrix version) using the RMA (robust multichip average)
algorithm. Differential expression analysis was performed using significant
analysis of microarrays, and a list of differentially expressed genes exhibiting
fold changes greater than 2 was generated. Pathway analysis was performed
using MetaCore software (Thomson Reuters).
Quantitative Real-Time PCR
qRT-PCR was performed as previously described (Miceli et al., 2012). Fold
change was measured using the DDCT method. Primer sequences used for
amplification were as follows: Arf, forward (Fwd) 50-GAGTACAGCAGCGGGA
GCAT-30 reverse (Rev) 50-ATCATCATCACCTGGTCCAGGATTCC-30; Trp53,
Fwd 50-CATCACCTCACTGCATGGAC-30 Rev 50-AAAAGATGACAGGGGCC
ATG-30; b-Actin, Fwd 50-TCACCCACACTGTGCCCATCTA-30 Rev 50-TAC
TCCTGCTTGCTGATCCACA-30; Histone 3.3, Fwd 50-CGTGAAATCAGACGC
TAGCAGAA-30 Rev 50-TCGCACCAGACGCTGAAAG-30; Oasl2, Fwd 50-ATC
ATTGTCCTTACCCACAGAG-30 Rev 50-TGCTGGTTTTGAGTCTCTGG-30;
Isg15, Fwd 50-CTGACTGTGAGAGCAAGCAGC-30 Rev 50-ACCAATCTTCTGG
GCAATCTG-30; Ifit3, Fwd 50-AGCACAGAAACAGATCACCAT-30 Rev 50-CAC
CCTGTCTTCCATATGACTG-30; Usp18, Fwd 50-TTCCCTCAGAGCTTGGAT
TTC-30 Rev 50-CCGGATGTAGGCACAGTAATG-30; Irf7, Fwd 50-TTGATCCG
CATAAGGTGTACG-30 Rev 50-TTCCCTATTTTCCGTGGCTG-30; Sfrp2, Fwd
50-GCCTGCAAAACCAAGAATGAG-30 Rev 50-GTCTTGCTCTTTGTCTCCA
GG-30; Stat1, Fwd 50-GCCGAGAACATACCAGAGAATC-30 Rev 50-GATGTAT
CCAGTTCGCTTAGGG-30; Ifnb1, Fwd 50-CCACCACAGCCCTCTCCATCAACT
AT-30 Rev 50-CAAGTGGAGAGCAGTTGAGGACATC-30; Il6, Fwd 50-CAAAG
CCAGAGTCCTTCAGAG-30 Rev 50-GTCCTTAGCCACTCCTTCTG-30; Tgtp1,
Fwd 50-CGAGTACTGGGAAGCTTGAAA-30 Rev 50-ATCAGGAGAAGGGAAA
GCATG-30.
IFN-b ELISA
Cell culture supernatants were concentrated using Vivaspin columns (GE
Healthcare) according to the manufacturer’s instructions. Mouse IFN-b levels
were measured using the Verikine Mouse Interferon Beta ELISA Kit (PBL Inter-
feron Source) according to the manufacturer’s instructions.
Immunohistochemistry
Annotated breast cancer tissue arrays were obtained from US Biomax
(Cat#BR1503a). Staining was performed using the Dako EnVision+ System-
HRP (DAB) according to the manufacturer’s instructions. Rabbit anti-
p14ARF (Bethyl) and mouse anti-iSG15 (Santa Cruz) were used at a 1:200
dilution. Quantification was performed by two separate individuals by blindly
scoring staining intensity on a 0–3 scale, with 0 being no staining and 3 being
strong widespread staining. A score of 0–1 was considered ‘‘low/no’’ staining,
and a score of 2–3 was considered ‘‘high.’’
Statistical Analysis.
Data are presented as means ± SD. Statistical differences between groups
were determined with p values obtained using two-sided, unpaired Student’s
t test. All data points represent n = 3. All images presented as ‘‘representative’’
were completed a minimum of three times.
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